APA (7th ed.) Citation

M, S., A, F., PA, T., J, B., G, B., K, T., . . . N, J. (2026). Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Blood cancer discovery, 7(3), 431. https://doi.org/10.1158/2643-3230.BCD-25-0345

Chicago Style (17th ed.) Citation

M, Swaminathan, et al. "Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study." Blood Cancer Discovery 7, no. 3 (2026): 431. https://doi.org/10.1158/2643-3230.BCD-25-0345.

MLA (9th ed.) Citation

M, Swaminathan, et al. "Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study." Blood Cancer Discovery, vol. 7, no. 3, 2026, p. 431, https://doi.org/10.1158/2643-3230.BCD-25-0345.